MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced that the company's Irvine, California, CLIA laboratory has received College of American Pathology (CAP) accreditation. CAP accreditation is an internationally recognized program established to improve patient safety by ensuring laboratories achieve the highest standards of excellence and exceed regulatory requirements. The first product offered through the Irvine laboratory is the company's recently launched ConfirmMDx™ for Prostate Cancer test, which provides urologists with a DNA-based epigenetic assay to help distinguish patients who have a true-negative prostate biopsy from those who may have occult cancer.
"CAP accreditation is the gold standard for quality, and MDxHealth is committed to delivering high quality clinical diagnostic and pharmaceutical laboratory services that surpass regulatory requirements," said Dr. Jan Groen, President and CEO of MDxHealth. "Our CLIA certified state-of-the-art facility is now fully accredited and licensed. Each day as our volumes for prostate cancer samples increases, quality and accuracy remain our priority."
Metabolic markers tied to increased risk of depression and anxiety, study finds